Catalyst Calendar

Mon, Sep 28, 2026

1 updates

7:30 AM

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development.

Presentation / Abstract • Phase 1Oral presentation Thu, Nov 19, 2026, 10:00 AM EDTbiohaven.com

Wed, Aug 26, 2026

1 updates

BHVN

2:36 AM

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Opakalim, the lead candidate from Biohaven's Kv7 platform, is a

biohaven.com

Tue, Aug 25, 2026

1 updates

BHVN

4:41 PM

Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University

NEW HAVEN, Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries (" Biohaven ") (NYSE: BHVN) and Yale University ("Yale") today announced that the U.S. District Court for the District of Delaware has entered judgment in their favor in the trade secret

biohaven.com